Alembic Pharmaceuticals receives USFDA tentative approval for Darolutamide Tablets – Business Upturn
Alembic Pharmaceuticals Limited has secured tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Darolutamide Tablets, 300 mg. This approval marks a significant step for Alembic as the product is therapeutically equivalent to Bayer HealthCare Pharmaceuticals Inc.'s Nubeqa Tablets, 300 mg. Darolutamide, an androgen receptor inhibitor, is indicated for the treatment…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
